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Several classes of antihypertensive agents have been in clinical use, including diuretics, a-
blockers, b-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II type 1
receptor blockers (ARB), and organic calcium channel blockers (CCBs). All these drugs are
being currently used in the treatment of Hypertension & various disease conditions of the
heart either alone or in combination. Cilnidipine is a new antihypertensive drug distin-
guished from other L-type Ca2þ channel blockers or even other antihypertensives, which
will be useful for selection of antihypertensive drugs according to the pathophysiological
condition of a patient.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Hypertension or high blood pressure 2. Antihypertensive drugsHypertension is one of the most important risk factors for
cardiovascular diseases, including ischemic and haemor-
rhagic stroke, dementia, ischemic heart disease, heart failure,
vision loss, and kidney failure. Hypertension is a multifacto-
rial andmultifaceted disease inwhich elevated blood pressure
is only one sign of multiple underlying physiological
abnormalities.1e3
Hypertension or high blood pressure is a leading cause of
death. The condition is often called a “silent killer” because its
symptoms can go undetected until damage to the body has
occurred. Because of this, it is one of the most significantly
under-diagnosed and under-treated medical conditions all
over the world. High blood pressure is usually a lifelong con-
dition. High blood pressure can occur at any age but is
particularly prevalent in people with a family history of high
blood pressure, people who are overweight or obese, people
with diabetes, and heavy drinkers.4,5m (K.S. Chandra).
2013, Cardiological SocietSeveral classes of antihypertensive agents have been in clinical
use, including diuretics, a-blockers, b-blockers, angiotensin
converting enzyme (ACE) inhibitors, angiotensin II type 1 re-
ceptor blockers (ARB), and organic calcium channel blockers
(CCBs). All these drugs are being currently used in the treatment
of hypertension and various disease conditions of the heart
either alone or in combination. They have specific indications,
therapeutic efficacies and limitations for the treatment of an
individualpatient.Apatienthastoconsumethesemedicines for
lifetime accommodating and adjusting to all their side effects.6
Clinically, an important goal of antihypertensive therapy is
to prevent the occurrence of cardiovascular complications. It
has been suggested that increased sympathetic activity is the
common link among many of the “non pressure-related”
coronary risk factors in hypertension. More importantly hy-
peractivity of sympathetic nervous system often triggers hy-
pertensive complications including ischemic heart disease,y of India. All rights reserved.
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importance of controlling sympathetic nerve activity in clin-
ical practice. Sympathetic nerve activity is one of the major
culprits implicated in the onset of hypertension. Julius7 re-
ported that the occurrence of a hyperkinetic state, that is, one
in which both cardiac output and heart rate are elevated, was
five times more frequently observed in patients with border-
line hypertension than in the normotensive population.3. Calcium channel blockers (CCBs)
Calcium channel blockers (CCBs), comprising two subclassese
dihydropyridines and non-dihydropyridines e have been for
many years one of the mainstays of hypertension therapy.
Calcium channel blockers (CCBs) share a commonmechanism
of action. However, the manner in which they exert their
pharmacological effects is different between subclasses. Dihy-
dropyridine (DHP) CCBs tend to be more potent vasodilators
thannon-dihydropyridine (non-DHP)agents,whereas the latter
have more marked negative inotropic effects. Both subclasses
have a similar capacity to lower BP; however, non-DHPs appear
to offer potential advantages in the management of patients
with chronic kidney disease and diabetic nephropathy.8,9
Dihydropyridines are among the most widely used drugs
for the management of cardiovascular disease. Introduced in
the 1960s, dihydropyridines have undergone several changes
to optimize their efficacy and safety. Four generations of
dihydropyridines are now available. The first-generation
nicardipine and nifedipine have proven efficacy against hy-
pertension. However, because of their short duration and
rapid onset of vasodilator action, these drugs weremore likely
to be associated with adverse effects. The new second gen-
eration slow-release and short-acting preparations like beni-
dipine, and efonidipine allowed better control of the
therapeutic effect and a reduction in some adverse effects.
The third-generation dihydropyridines, amlodipine and azel-
nidipine exhibit more stable pharmacokinetics, are less
cardio-selective and, consequently, well tolerated in patients
with heart failure. The fourth-generation highly lipophilic
dihydropyridines, lercanidipine and lacidipine are now avail-
able which provide a real degree of therapeutic comfort in
terms of stable activity, a reduction in adverse effects and a
broad therapeutic spectrum, especially in myocardial
ischemia and potentially in congestive heart failure.10
Ca2þ channel blockers have been categorized according to
selectivity for the voltage-dependent Ca2þ channels in vascular
smoothmuscleagainst those incardiac tissue,11chemicalclass,
and binding affinity to receptors in Ca2þ channels, chemical
structure, or lipophilicities.12 In 1996, a useful classificationwas
proposed to divide Ca2þ channel blockers into three groups e
first, second, and third generation, which were fundamentally
based on the effects on Ca2þ channel receptor-binding proper-
ties, tissue selectivity, and pharmacokinetic profile.134. Calcium channels and CCBs
Among antihypertensive drugs, calcium channel blockers,
which inhibit L-type voltage-gated calcium channels, arepotent vasodilators, and have been used as a first- or second-
line drug. Dihydropyridine-class calcium channel blockers are
categorized into three generations according to the length of
activity, and long-acting calcium channel blockers cause less
activation of sympathetic nervous system, and are reported to
offer beneficial action compared with short-action agents.
Furthermore, novel types of calcium channel blockers have
been developed that possess the blocking action on other
calcium channel subtypes (T- and N-type), and exert agent-
specific action apart from their class effects, such as the ef-
fects on heart rate and renin/aldosterone release. These
additional benefits conferred by T/N-type calcium channel
blockade are anticipated to provide organ protective actions in
the treatment of hypertension, in addition to the blood
pressure-lowering effect of L-type calcium channel blockade.
In conclusion, novel calcium channel blockers with sustained
activity and T/N-type calcium channel-blocking action could
provide more beneficial effects than classical blockers, and
may expand the clinical utility of these agents.14
The voltage-gated calcium channel consists of 4 subunits,
a1, a2-d, b and g. An a1 subunit is the dominant component of
the calcium channels and constitutes pore structure for ion
conduction. Ten different a1 subunits have been reported and
each of them has specific distribution and ion conductance of
its channels. These distinct subunits characterize the channel
properties of L-, N-, T-, P-, Q- and R-type calcium channels.15,16
Of these channels, L-type calcium channels are the main
targets of the CCB. Based on the chemical structure, CCBs are
categorized into 3 subgroups; benzothiazepines (e.g., diltia-
zem and clenazem), phenylalkylamines (e.g., verapamil and
gallopamil) and dihydropyridines (e.g., nifedipine, nicardi-
pine, felodipine, amlodipine, aranidipine, azelnidipine, cil-
nidipine, efonidipine, manidipine and nilvadipine). The
differences in chemical structures would provide heteroge-
neity in the action of these agents. All CCBs block the calcium
influx by binding to the a1 subunit,17 and inhibit cell excit-
ability. Although the CCB inhibits calcium currents through
L-type calcium channels, some CCBs possess the ability to
block other calcium channels (Fig. 1).
Cilnidipine has been extensively studied by researchers in
its preclinical and clinical development phases. Renopro-
tective, neuroprotective and cardioprotective effects of cil-
nidipine have been demonstrated in clinical practice or
animal examinations. It is noticed that cilnidipine may have
pleiotropic effects besides N-type Ca2þ channel-blocking ac-
tion. Therefore, the inhibition of N-type Ca2þ channels may
provide a new strategy for the treatment of cardiovascular
diseases. This article reviews the current understanding of the
pharmacological profile and clinical utility of cilnidipine as a
unique antihypertensive drug.
Cilnidipine is a recently developed CCB, and possesses
both L- and N-type calcium channels blocking activity. Since
N-type calcium is distributed along the nerve and in the brain,
cilnidipine is anticipated to exert specific action on nerve ac-
tivity, such as inhibition of the sympathetic nervous system.18
Uneyama et al demonstrated that submicro molecular con-
centrations of cilnidipine effectively suppressed N-type Ca2þ
channel currents in isolated sympathetic neurons.19
They further compared the inhibitory effect of various
dihydropyridines on cardiac L-type Ca2þ channels in isolated
Fig. 1 e Diagrammatic representation of L/N dual action of cilnidipine.
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superior cervical ganglion neurons obtained from Wistar
rats.20 In that study, all dihydropyridines, except cilnidipine,
showed a small inhibitory effect at a concentration of 1 mM.
Furthermore, it was noted that the selectivity for L-type/N-
type of Ca2þ channels differed markedly among the com-
pounds tested, where nifedipine showed high selectivity for L-
type Ca2þ channels and cilnidipine blocked both L- and N-type
of Ca2þ channels. The N-type channel-blocking action of cil-
nidipine has also been confirmed by Takahara A et al in IMR-
32 human neuroblastoma cells.21 Cilnidipine inhibits N-type
Ca2þ channels more potently than other Ca2þ channel
blockers and several in vitro studies conducted by Nap A et al
(2004) have demonstrated that cilnidipine attenuates norepi-
nephrine release from sympathetic nerve endings.22,23
Furthermore, such effects have been observed in in vivo ex-
periments using anesthetized rats24 and dogs.25 The car-
dioprotective action of cilnidipine has been analyzed in a
rabbit model of myocardial infarction, in which cilnidipine
decreased the myocardial interstitial norepinephrine levels
during ischemia and reperfusion periods, leading to reduction
of the myocardial infarct size and incidence of ventricular
premature beats.26 Furthermore, in vivo experimental data
have suggested that cilnidipine shows antianginal effects in
the experimental model of vasopressin-induced angina and
improvement of the ventricular repolarization abnormality in
the canine model of long QT syndrome.27,28
Sympatholytic profiles of cilnidipine observed in both
in vitro and in vivo, are also observed in clinical practice.19,24
In clinical studies, conducted by Nagahama S et al (2007) and
Iimura O et al (1993) the antihypertensive effect of cilnidipine
has been demonstrated in hypertensive patients,29 and also in
patients with severe hypertension.30 In a study conducted in
2920 hypertensive patients, treatment with cilnidipine and
angiotensin receptor blocker showed significant reductions in
heart rate, particularly in those with a higher baseline heart
rate75 beats/min, whereas there were few adverse reactions
associated with central nervous functions.29 Hoshide et al31
demonstrated that the reductions in heart rate weresignificantly greater in the cilnidipine group than the amlo-
dipine group in a 24-h ambulatory blood pressure monitoring
study with hypertensive patients. Furthermore, cilnidipine
has been clinically demonstrated to be effective for morning
hypertension and white-coat hypertension, which is closely
associated with sympathetic nerve activation.32,33 The CAN-
DLE trial34 and other clinical studies have demonstrated that
cilnidipine improves left ventricular function.35
Hypertension is one of the most important risk factors for
the progression of renal disease.36,37 In the follow-up study of
the multiple risk factor intervention trial (MRFIT), a strong,
graded relation between blood pressure and end-stage renal
disease was identified.38 Moreover, chronic renal dysfunc-
tion,39 proteinuria or albuminuria40 are independent risk
factors for cerebrovascular and cardiovascular diseases. Thus,
the treatment of hypertension constitutes a crucial strategy to
minimize the development of renal disease and to reduce the
risk of cardiovascular events.
In clinical studies, Rose and Ikebukoro41 demonstrated that
cilnidipine significantly decreased urinary albumin excretion
without affecting serum creatinine concentration in hyper-
tensive patients, which is comparable to the angiotensin con-
verting enzyme inhibitor benazepril. Other studies conducted
by Kojima S (2004) and Tsuchihashi T et al (2005) have shown
that the renal protective effect of cilnidipine was greater than
pure L-type Ca2þ channel blockers.42,43 Furthermore, the
combination of cilnidipine and valsartan was shown to
decrease the albumin/creatine ratio more markedly than val-
sartan alone.44 Recently, the multicenter, open labeled and
randomized trial of Cilnidipine versus Amlodipine Random-
ized Trial for Evaluation in Renal disease (CARTER) has shown
that cilnidipine is superior to amlodipine in preventing the
progression of proteinuria in patients with hypertension and
chronic renal disease when coupled with a renineangiotensin
system inhibitor.45 Recently, prevalence of cardiovascular
disease and cardiovascular mortality have been suggested to
be closely associated with renal function; namely, car-
dioerenal connection.46 Thus, the renal protective effects of
cilnidipine may secondarily contribute to cardioprotection.
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(2011) have demonstrated the beneficial effects of L- and N-
type calcium channel blocker on glucose and lipidmetabolism
and renal function in patients with hypertension and type II
diabetes mellitus.47
A recent study by Fan et al (2011) indicates that cilnidipine
relaxes human arteries through Ca2þ channel antagonism and
increases production of nitric oxide by enhancement of
endothelial nitric oxide synthase in the human internal
thoracic artery.48
Ranjan Shetty, G Vivek et al (2013) have conducted a study
in 27 patients of essential hypertension with amlodipine-
induced ankle edema and concluded that therapy with cil-
nidipine resulted in complete resolution of amlodipine-
induced edema in all the cases without significant wors-
ening of hypertension or tachycardia. Cilnidipine is an
acceptable alternative antihypertensive for patients with
amlodipine-induced edema.49
Xu Guo-Liang et al (2012) conducted a meta-analysis of the
efficacy and safety of cilnidipine in Chinese patients withmild
to moderate essential hypertension, of 11 clinical trials and
concluded that cilnidipine is a useful agent to treat mild to
moderate essential hypertension.505. Conclusion
Cilnidipine is a promising 4th generation Ca2þ channel blocker
with a rational pharmacological profile; i.e. dual L/N-type Ca2þ
channel-blocking action. The blockade of N-type Ca2þ chan-
nels effectively suppresses neurohumoral regulation in the
cardiovascular system, including sympathetic nervous sys-
tem and renineangiotensinealdosterone system. Thus, cil-
nidipine is expected to be favorable for various types of
complications of hypertension. The currently described in-
formation suggests that cilnidipine is a new type of antihy-
pertensive drug distinguished from other L-type Ca2þ channel
blockers or even other antihypertensives, which will be useful
for selection of antihypertensive drugs according to the
pathophysiological condition of a patient.Conflicts of interest
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